HealthEquity (HQY)
(Delayed Data from NSDQ)
$64.83 USD
+1.45 (2.29%)
Updated Jun 9, 2023 04:00 PM ET
After-Market: $64.83 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
HQY 64.83 +1.45(2.29%)
Will HQY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for HQY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HQY
How Much Upside is Left in HealthEquity (HQY)? Wall Street Analysts Think 26.59%
Here's Why HealthEquity (HQY) is a Strong Momentum Stock
HQY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why HealthEquity (HQY) is a Strong Momentum Stock
Zacks Industry Outlook Highlights Medpace, HealthEquity and Apollo Medical
3 Medical Services Stocks to Buy Amid Improving Industry Trends
Other News for HQY
American Express, EQT, HealthEquity And A Major Wireless Carrier With A 7% Dividend Yield: CNBC's 'Final Trades'
HealthEquity: Revising To Buy On Earnings Power, Asset Factors
HealthEquity price target raised to $71 from $69 at Deutsche Bank
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Cogent Biosciences (COGT) and Mersana Therapeutics (MRSN)
SVB Securities Keeps Their Buy Rating on Healthequity (HQY)